Does Citalopram Cause Cancer?
No, citalopram does not cause cancer in humans and may actually reduce cancer risk. The most recent and highest quality evidence shows that citalopram use is associated with a lower risk of overall cancer morbidity and cancer-related mortality 1.
Human Evidence: Protective Association
The strongest clinical evidence comes from a large prospective cohort study of 421,529 participants with 13.6 years of median follow-up, which found 1:
- Citalopram specifically was associated with reduced cancer risk among SSRIs studied, alongside fluoxetine and sertraline 1
- Overall SSRI use (including citalopram) reduced cancer morbidity by 11% (HR 0.89,95% CI 0.85-0.94) 1
- Cancer-related mortality was reduced by 9% among SSRI users (HR 0.91,95% CI 0.84-0.99) 1
- Colorectal cancer risk was reduced by 25% (HR 0.75,95% CI 0.65-0.86) 1
Breast Cancer Patients: No Increased Risk
Multiple studies specifically examined citalopram in breast cancer patients taking tamoxifen 2, 3:
- Citalopram does not reduce tamoxifen's effectiveness at preventing breast cancer recurrence (adjusted OR = 1.1,95% CI 0.7-1.7) 2
- No increased recurrence risk was observed even among regular citalopram users with >30% overlap with tamoxifen therapy (adjusted OR = 0.85,95% CI 0.42-1.7) 3
- Citalopram is the preferred SSRI for breast cancer patients on tamoxifen because it has limited potency to inhibit CYP2D6, unlike fluoxetine or paroxetine which reduce tamoxifen's active metabolite formation 4
Animal Studies: Context and Relevance
The FDA label reports animal carcinogenicity findings that require proper interpretation 5:
- Mice showed no carcinogenicity at doses up to 240 mg/kg/day (20 times the maximum human dose) 5
- Rats showed increased small intestine carcinoma at 8-24 mg/kg/day (1.3-4 times human doses on mg/m² basis) 5
- The FDA explicitly states: "The relevance of these findings to humans is unknown" 5
Why Animal Findings Don't Apply to Humans
- The rat finding occurred at doses producing toxic effects and has not been replicated in any human epidemiological study 5
- Human data spanning decades shows the opposite effect - protective associations rather than increased cancer risk 1
- Regulatory animal testing often produces findings that don't translate to human outcomes, which is why post-marketing surveillance and epidemiological studies are critical 5
Laboratory Evidence: Potential Anti-Cancer Properties
Recent in vitro research suggests citalopram may have direct anti-tumor effects 6:
- Citalopram induced apoptosis in both triple-negative (MDA-MB231) and ER-positive (MCF-7) breast cancer cells 6
- Cell cycle arrest was triggered with upregulation of growth arrest genes (GADD45a, p21) 6
- Pro-apoptotic pathways were activated with increased Bax, cytochrome c, and NF-κB expression 6
A 1995 review also noted that citalopram demonstrated antineoplastic properties in experimental models 7.
Critical Caveat: Escitalopram Concerns
Do not confuse citalopram with escitalopram - while chemically related, recent animal studies show escitalopram (the S-enantiomer) increased tumor growth and metastasis in multiple rodent cancer models by 1.4-2.3 fold 8. This has not been studied in humans and requires further investigation 8.
Clinical Bottom Line
- Citalopram is safe from a cancer risk perspective and may offer protective benefits 1
- For breast cancer patients on tamoxifen, citalopram is the preferred SSRI due to minimal CYP2D6 inhibition 2, 3, 4
- Animal carcinogenicity findings have no established human relevance and are contradicted by large-scale human data 5, 1
- Continue standard dosing guidelines (maximum 40 mg/day for adults <60 years, 20 mg/day for ≥60 years) without cancer-related modifications 9
Human epidemiological evidence consistently demonstrates that citalopram does not increase cancer risk and may reduce it, making it an appropriate choice for depression treatment in patients with or without cancer history 1.